Aker BioMarine ASA (OSL:AKBM)
Norway · Delayed Price · Currency is NOK | Market Cap | 8.47B +64.8% |
| Revenue (ttm) | 2.19B +11.6% |
| Net Income | -220.11M |
| EPS | -2.51 |
| Shares Out | 87.70M |
| PE Ratio | n/a |
| Forward PE | 34.05 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 15,438 |
| Open | 95.40 |
| Previous Close | 95.50 |
| Day's Range | 94.10 - 96.90 |
| 52-Week Range | 55.00 - 118.00 |
| Beta | 0.30 |
| Analysts | Buy |
| Price Target | 127.04 (+31.51%) |
| Earnings Date | Jul 10, 2026 |
About Aker BioMarine ASA
Aker BioMarine ASA, a biotech innovator, develops and supplies krill-derived products for consumer health and wellness worldwide. The company operates through three segments: Human Health Ingredients (HHI), Consumer Health Products, and Emerging Business. The Human Health Ingredients segment sells B2B krill oil supplements for humans under the Superba Krill brand; supplements for brain health under the LYSOVETA brand; and marine-origin DHA omega-3 from microalgae under the Revervia brand name, as well as advanced phospholipid technology under P... [Read more]
News
Aker BioMarine ASA Earnings Call Transcript: Q1 2026
Revenue grew 13% year-over-year to $57.3 million, driven by record krill oil sales and strong Human Health Ingredients performance. Adjusted EBITDA rose 34%, and the company completed a major refinancing, maintaining solid liquidity and leverage metrics.
Aker BioMarine ASA Slides: Q1 2026
Aker BioMarine ASA has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 30, 2026.
Aker BioMarine ASA Earnings release: Q1 2026
Aker BioMarine ASA released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
Aker BioMarine ASA (OSL:AKBM) Q1 2026 Earnings Report Preview: What To Expect
Aker BioMarine ASA (OSL:AKBM) Q1 2026 Earnings Report Preview: What To Expect
World’s largest krill harvester at centre of row over ‘blue tick’ sustainability label
Aker QRILL is facing criticism of its fishery management amid calls by environmentalists for curbs on Antarctic fishing of the keystone species Environmental groups have objected to the recommendation...
Aker BioMarine ASA Earnings Call Transcript: Q4 2025
Q4 2025 saw 6% revenue and 66% EBITDA growth, led by a 28% surge in Human Health Ingredients, while consumer health declined 8%. Strategic focus is on maximizing Human Health Ingredients value, with strong guidance for 2026 and ongoing capacity expansion.
Aker BioMarine ASA Annual report: Q4 2025
Aker BioMarine ASA has published its Q4 2025 annual report on February 12, 2026.
Aker BioMarine ASA Earnings release: Q4 2025
Aker BioMarine ASA released its Q4 2025 earnings on February 12, 2026, summarizing the period's financial results.
Aker BioMarine ASA Slides: Q4 2025
Aker BioMarine ASA has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 12, 2026.
Aker BioMarine ASA (OSL:AKBM) Q4 2025 Earnings Report Preview: What To Look For
Aker BioMarine ASA (OSL:AKBM) Q4 2025 Earnings Report Preview: What To Look For
Aker BioMarine ASA Earnings Call Transcript: Q3 2025
Q2 and Q3 2025 saw double-digit revenue and EBITDA growth, led by Human Health Ingredients and Consumer Health Products, with improved margins and operational leverage. The company is addressing production challenges, expanding in Asia, and expects continued growth, while managing risks from tariffs and restructuring.
Aker BioMarine ASA Earnings release: Q3 2025
Aker BioMarine ASA released its Q3 2025 earnings on October 31, 2025, summarizing the period's financial results.
Aker BioMarine ASA Slides: Q3 2025
Aker BioMarine ASA has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 31, 2025.
Aker BioMarine ASA (OSL:AKBM) Q3 2025 Earnings Report Preview: What To Expect
Aker BioMarine ASA (OSL:AKBM) Q3 2025 Earnings Report Preview: What To Expect
Aker BioMarine ASA Earnings Call Transcript: Q2 2025
Q2 2025 saw 12% revenue growth and 41% higher adjusted EBITDA, led by strong human health and consumer health segments. Operational leverage, cost reallocation, and product innovation drove margin gains, while a $15 million impairment was taken on the protein plant due to tariff uncertainty.
Aker BioMarine ASA Quarterly report: Q2 2025
Aker BioMarine ASA has published its Q2 2025 quarterly earnings report on July 11, 2025.
Aker BioMarine ASA Slides: Q2 2025
Aker BioMarine ASA has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on July 11, 2025.
What To Expect From Aker BioMarine ASA (OSL:AKBM) Q4 2024 Earnings
What To Expect From Aker BioMarine ASA (OSL:AKBM) Q4 2024 Earnings